Literature DB >> 7688756

N-acetyl-D-glucosamine medium improves recovery of Haemophilus influenzae from sputa of patients with cystic fibrosis.

L V Möller1, L van Alphen, H Grasselier, J Dankert.   

Abstract

A modified selective medium supplemented with N-acetyl-D-glucosamine (NAG), hemin, and NAD plus two cefsulodin disks, for primary isolation of nonencapsulated Haemophilus influenzae from sputum of patients with cystic fibrosis, is described. Isolation of H. influenzae from this medium, designated NAG medium, was compared with recovery by standard media and immunochemical detection of H. influenzae with monoclonal antibody 8BD9. The H. influenzae recovery rate increased from 31% with standard media to 42% with NAG medium. H. influenzae was detected by immunoperoxidase staining in 54% of the sputum specimens. The results of this study demonstrate that NAG medium improves H. influenzae recovery, although immunoperoxidase staining is superior for detection of H. influenzae from sputum of cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688756      PMCID: PMC265670          DOI: 10.1128/jcm.31.7.1952-1954.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Microscopic and baceriologic analysis of expectorated sputum.

Authors:  P R Murray; J A Washington
Journal:  Mayo Clin Proc       Date:  1975-06       Impact factor: 7.616

2.  Haemophilus in the upper respiratory tract of children. A bacteriological, serological and clinical investigation.

Authors:  M Kilian; J Heine-Jensen; P Bülow
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1972

3.  Osmotically stable L forms of Haemophilus influenzae and their significance in testing sensitivity to penicillins.

Authors:  J R May; D E Roberts; A Ingold; S V Want
Journal:  J Clin Pathol       Date:  1974-07       Impact factor: 3.411

4.  A selective medium for the isolation of haemophilus from sputum.

Authors:  K G Baber
Journal:  J Med Lab Technol       Date:  1969-10

5.  Use of selective media in bacteriological investigation of patients with chronic suppurative respiratory infection.

Authors:  D E Roberts; P Cole
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

6.  Detection of Haemophilus influenzae with monoclonal antibody.

Authors:  K Groeneveld; L van Alphen; N J Geelen-van-den Broek; P P Eijk; H C Zanen; R J van Ketel
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

7.  Isolation of spheroplastic forms of Haemophilus influenzae from sputum in conventionally treated chronic bronchial sepsis using selective medium supplemented with N-acetyl-D-glucosamine: possible reservoir for re-emergence of infection.

Authors:  D Roberts; E Higgs; A Rutman; P Cole
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

8.  A taxonomic study of the genus Haemophilus, with the proposal of a new species.

Authors:  M Kilian
Journal:  J Gen Microbiol       Date:  1976-03

9.  Haemophilus influenzae is frequently detected with monoclonal antibody 8BD9 in sputum samples from patients with cystic fibrosis.

Authors:  L V Möller; G J Ruijs; H G Heijerman; J Dankert; L van Alphen
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

10.  Antibiotic treatment of Haemophilus influenzae and Haemophilus parainfluenzae infections in patients with cystic fibrosis.

Authors:  T Pressler; M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1984-07
View more
  2 in total

1.  Variation in metabolic enzyme activity of persistent Haemophilus influenzae in respiratory tracts of patients with cystic fibrosis.

Authors:  L V Möller; H Grasselier; J Dankert; L van Alphen
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

2.  Antimicrobial susceptibility of Haemophilus influenzae in the respiratory tracts of patients with cystic fibrosis.

Authors:  L V Möller; A G Regelink; H Grasselier; L van Alphen; J Dankert
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.